

IN THE CLAIMS

(For the Examiner's convenience all claims that will be pending upon entry of this Amendment are reproduced below.)

Please cancel claims 2, 3, 5-7, 10, 22, 24-28, 34-42, 45, 46 and 48 without prejudice.

43. (Unchanged) A composition comprising human tumor cells that:
- (i) are conjugated to a hapten;
 - (ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;
 - (iii) are autologous to said patient; and
 - (iv) have been rendered incapable of growing in the body of a human upon injection therein;
- said composition eliciting an inflammatory immune response against the tumor of said human wherein said tumor is not melanoma.
44. (Unchanged) A method for treating a malignant tumor in a human patient comprising administering to the patient
- (a) a composition comprising a therapeutically effective amount of human tumor cells that:
 - (i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting at least one of the following upon administration to said patient with an adjuvant: an inflammatory immune response against the tumor of said patient; a delayed-type hypersensitivity response against the tumor of said patient and activated T lymphocytes that infiltrate the tumor of said patient wherein said malignant tumor is not melanoma.

47. (Unchanged) A method of treating a malignant tumor in a human patient comprising administering to the patient a composition comprising a therapeutically effective amount of human tumor cells that:

(i) are conjugated to a hapten;

(ii) are of the same tumor type as a malignant tumor of a patient for treatment of whom the composition is intended;

(iii) are autologous to said patient; and

(iv) have been rendered incapable of growing in the body of a human upon injection therein;

said composition eliciting at least one of the following upon administration to said patient with an adjuvant: an inflammatory immune response against the tumor of said human; a delayed-type

hypersensitivity response against the tumor of said human and activated T lymphocytes that infiltrate the tumor of said human; and

repeating said administration at least six times at spaced apart intervals.

Please add the following new claims:

--49. The composition of claim 43 wherein said tumor cells are selected from lung, colon, breast, kidney, and prostate tumor cells.

61 --50. The composition of claim 43 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5 sulfonic 1-naphtyl) ethylene diamine.

--51. The composition of claim 43 wherein said hapten is dinitrophenyl.

--52. The composition of claim 43 further comprising an adjuvant.

--53. The composition of claim 52 wherein said adjuvant is *Bacillus Calmette-Guerin*.

W/SI --54. A composition of claim 43 further comprising a carrier.

--55. A composition of claim 54 wherein said carrier is selected from the group consisting of saline solution and culture medium.

--56. The method of claim 44 wherein said tumor cells are selected from lung, colon, breast, kidney, and prostate tumor cells.

52
61
--57. The method of claim 44 useful for the treatment of cancer selected from the group consisting of lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer.

--58. The method of claim 44 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine.

--59. The method of claim 44 wherein said hapten is dinitrophenyl.

--60. The method of claim 44 further comprising administering a therapeutically effective amount of cyclophosphamide prior to administration of said composition.

--61. The method of claim 60 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M² of cyclophosphamide

prior to administration of said composition.

--62. The method of claim 60 further comprising sensitizing the patient with a therapeutically effective amount of 1-fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.

--63. The method of claim ~~44~~ wherein said composition comprises an adjuvant.

I
G1
--64. The method of claim ⁴⁴~~63~~ wherein said adjuvant is *Bacillus Calmette-Guerin*.

--65. The method of claim 47 wherein said tumor cells are selected from melanoma, lung, colon, breast, kidney, and prostate tumor cells.

153
--66. The method of claim 47 useful for the treatment of cancer selected from the group consisting of melanoma cancer, lung cancer, colon cancer, breast cancer, kidney cancer, and prostate cancer.

--67. The method of claim 47 wherein said hapten is selected from the group consisting of dinitrophenyl, trinitrophenyl, and N-iodoacetyl-N'-(5-sulfonic 1-naphtyl) ethylene diamine.

--68. The method of claim 47 wherein said hapten is dinitrophenyl.

--69. The method of claim 47 further comprising administering a therapeutically effective amount of cyclophosphamide prior to administration of said composition.

54
--70. The method of claim 47 wherein said therapeutically effective amount of cyclophosphamide is administered only prior to the first administration of said composition.

61
--71. The method of claim 69 wherein said therapeutically effective amount of cyclophosphamide comprises administering a dose of about 300 mg/M² of cyclophosphamide prior to administration of said composition.

--72. The method of claim 47 further comprising sensitizing the patient with a therapeutically effective amount of 1-fluoro-2,4-dinitrobenzene prior to administering cyclophosphamide.

47
--73. The method of claim 47 wherein said composition comprises an adjuvant.

I
--74. The method of claim 47 wherein said adjuvant is *Bacillus Calmette-*

Guerin.